RU2742888C2 - Способ лечения с3-гломерулопатии - Google Patents

Способ лечения с3-гломерулопатии Download PDF

Info

Publication number
RU2742888C2
RU2742888C2 RU2018129378A RU2018129378A RU2742888C2 RU 2742888 C2 RU2742888 C2 RU 2742888C2 RU 2018129378 A RU2018129378 A RU 2018129378A RU 2018129378 A RU2018129378 A RU 2018129378A RU 2742888 C2 RU2742888 C2 RU 2742888C2
Authority
RU
Russia
Prior art keywords
compound
person
group
independently selected
glomerulopathy
Prior art date
Application number
RU2018129378A
Other languages
English (en)
Russian (ru)
Other versions
RU2018129378A (ru
RU2018129378A3 (enExample
Inventor
Петрус БЕККЕР
Original Assignee
Кемосентрикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Кемосентрикс, Инк. filed Critical Кемосентрикс, Инк.
Publication of RU2018129378A publication Critical patent/RU2018129378A/ru
Publication of RU2018129378A3 publication Critical patent/RU2018129378A3/ru
Application granted granted Critical
Publication of RU2742888C2 publication Critical patent/RU2742888C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
RU2018129378A 2016-01-14 2017-01-12 Способ лечения с3-гломерулопатии RU2742888C2 (ru)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201662278788P 2016-01-14 2016-01-14
US62/278,788 2016-01-14
US201662280346P 2016-01-19 2016-01-19
US62/280,346 2016-01-19
US201662347450P 2016-06-08 2016-06-08
US62/347,450 2016-06-08
US201662397527P 2016-09-21 2016-09-21
US62/397,527 2016-09-21
PCT/US2017/013132 WO2017123716A1 (en) 2016-01-14 2017-01-12 Method of treating c3 glomerulopathy

Publications (3)

Publication Number Publication Date
RU2018129378A RU2018129378A (ru) 2020-02-14
RU2018129378A3 RU2018129378A3 (enExample) 2020-05-20
RU2742888C2 true RU2742888C2 (ru) 2021-02-11

Family

ID=59312069

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2018129378A RU2742888C2 (ru) 2016-01-14 2017-01-12 Способ лечения с3-гломерулопатии

Country Status (18)

Country Link
US (3) US20170202821A1 (enExample)
EP (1) EP3402486B1 (enExample)
JP (4) JP7339733B2 (enExample)
KR (1) KR102767008B1 (enExample)
CN (1) CN108601790A (enExample)
AU (1) AU2017207359C1 (enExample)
BR (2) BR122024002810A2 (enExample)
CA (1) CA3010735C (enExample)
ES (1) ES3026359T3 (enExample)
IL (1) IL260539B (enExample)
MA (1) MA43872A (enExample)
MX (2) MX2022006069A (enExample)
NZ (1) NZ744083A (enExample)
RU (1) RU2742888C2 (enExample)
SG (1) SG11201805828YA (enExample)
TW (1) TWI791423B (enExample)
WO (1) WO2017123716A1 (enExample)
ZA (1) ZA201804513B (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3508477B1 (en) 2008-12-22 2021-11-10 ChemoCentryx, Inc. C5ar antagonists
DK2585064T3 (en) 2010-06-24 2017-07-24 Chemocentryx Inc C5aR antagonists
EP3200791B1 (en) 2014-09-29 2020-04-22 ChemoCentryx, Inc. Processes and intermediates in the preparation of c5ar antagonists
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
WO2017035409A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
AR106018A1 (es) 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
MA43872A (fr) 2016-01-14 2021-05-19 Chemocentryx Inc Procédé de traitement d'une glomérulopathie à c3
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
CA3053818A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders
WO2019021091A1 (en) * 2017-07-27 2019-01-31 Procter & Gamble International Operations Sa SPRAYABLE, STABLE PHASE REFRIGERATING COMPOSITIONS COMPRISING SUSPENDED PARTICLES
WO2019028284A1 (en) 2017-08-02 2019-02-07 Achillion Pharmaceuticals, Inc. THERAPEUTIC REGIMES FOR THE TREATMENT OF NOCTURNAL PAROXYSTIC HEMOGLOBINURIA
JP2021525860A (ja) * 2018-05-25 2021-09-27 アキリオン ファーマシューティカルズ，インコーポレーテッド 補体代替経路関連腎症バイオマーカー
US11814391B2 (en) 2018-09-06 2023-11-14 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for the treatment of medical disorders
KR20210057086A (ko) 2018-09-06 2021-05-20 아칠리온 파르마세우티칼스 인코포레이티드 다니코판의 형태체 형태
EP3856164B1 (en) 2018-09-25 2024-08-07 Achillion Pharmaceuticals, Inc. Morphic forms of complement factor d inhibitors
LT3886820T (lt) 2018-11-30 2023-06-12 Chemocentryx, Inc. Kapsulės vaisto formos
MX2021007329A (es) 2018-12-17 2021-09-21 Achillion Pharmaceuticals Inc Dosificacion dirigida para el tratamiento de trastornos mediados por el complemento.
US11149009B2 (en) 2019-03-11 2021-10-19 Inflarx Gmbh Fused piperidinyl bicyclic and related compounds as modulators of C5A receptor
KR20220004024A (ko) 2019-03-22 2022-01-11 아칠리온 파르마세우티칼스 인코포레이티드 보체 매개 장애의 치료를 위한 약제학적 조성물
WO2022028586A1 (en) * 2020-08-07 2022-02-10 Kira Pharmaceuticals (Suzhou) Ltd. Compounds as c5ar inhibitors
IL303776A (en) * 2020-12-21 2023-08-01 Chemocentryx Inc Treatment of C3 glomerulopathy using a C5A inhibitor
CN115192563B (zh) * 2022-05-09 2023-10-13 北京大学第一医院 C3a/C3aR通路拮抗剂治疗原发性膜性肾病的用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2197288C2 (ru) * 1999-08-03 2003-01-27 Тверская медицинская академия Способ лечения больных хроническим гломерулонефритом
US20100104558A1 (en) * 2006-10-31 2010-04-29 Inserm (Inetitut National De La Sante Et La Recherche Medicale ) Use of an EGFR Antagonist for the Treatment of Glomerolonephritis
US20120225056A1 (en) * 2008-11-10 2012-09-06 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
US20130172347A1 (en) * 2010-06-24 2013-07-04 Pingchen Fan C5ar antagonists

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1268002A (en) 1917-09-12 1918-05-28 William M Goodwin Measuring instrument.
US4166452A (en) 1976-05-03 1979-09-04 Generales Constantine D J Jr Apparatus for testing human responses to stimuli
US4256108A (en) 1977-04-07 1981-03-17 Alza Corporation Microporous-semipermeable laminated osmotic system
US4265874A (en) 1980-04-25 1981-05-05 Alza Corporation Method of delivering drug with aid of effervescent activity generated in environment of use
US4686100A (en) 1985-04-02 1987-08-11 The Board Of Trustees Of The Leland Stanford Junior University Method for the treatment of adult respiratory distress syndrome
KR20010082184A (ko) 1998-08-28 2001-08-29 추후제출 p38-α 키나제의 저해체
JP2003532726A (ja) 2000-05-05 2003-11-05 スミスクライン・ビーチャム・コーポレイション 新規抗感染症薬
DE60143297D1 (de) 2000-08-10 2010-12-02 Mitsubishi Tanabe Pharma Corp 3-substituierte harnstoffderivate und deren medizinische verwendung
CN1474803B (zh) 2000-09-14 2012-11-21 田边三菱制药株式会社 酰胺衍生物及其制备药物的用途
CN1454086A (zh) 2000-09-29 2003-11-05 神经能质公司 高亲和性小分子C5a受体调节物
PT1425042E (pt) 2001-08-17 2007-07-11 Tanox Inc Inibidores de via complementar que se ligam a c5a sem impedir a formação de c5b
US7427615B2 (en) 2001-09-21 2008-09-23 Mitsubishi Pharma Corporation 3-substituted-4-pyrimidone derivatives
ITMI20012025A1 (it) 2001-09-28 2003-03-28 Dompe Spa Sali di ammonio quaternari di omega-amminoalchilammidi di acidi r 2-aril-propionici e composizioni farmaceutiche che li contengono
US20030195192A1 (en) 2002-04-05 2003-10-16 Fortuna Haviv Nicotinamides having antiangiogenic activity
EP1487796A4 (en) 2002-03-28 2005-11-16 Neurogen Corp SUBSTITUTED BIARYLAMIDES AS MODULATORS OF THE C5A RECEPTOR
JP2006508894A (ja) 2002-03-28 2006-03-16 ニューロジェン・コーポレーション Ｃ５ａ受容体調節因子としての置換テトラヒドロイソキノリン
CA2480082A1 (en) 2002-03-29 2003-10-16 Neurogen Corporation Combination therapy for the treatment of conditions with pathogenic inflammatory components
US20040014744A1 (en) 2002-04-05 2004-01-22 Fortuna Haviv Substituted pyridines having antiangiogenic activity
WO2004014905A1 (en) 2002-08-08 2004-02-19 Boehringer Ingelheim Pharmaceuticals, Inc. Substituted benzimidazole compounds
US7169775B2 (en) 2002-08-21 2007-01-30 Neurogen Corporation Amino methyl imidazoles as C5a receptor modulators
FR2846654A1 (fr) 2002-11-05 2004-05-07 Servier Lab Nouveaux derives de la 2,3-dihydro-4(1h)-pyridinone, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
WO2004043223A2 (en) 2002-11-05 2004-05-27 The Regents Of The University Of Michigan Compositions and methods for the diagnosis and treatment of sepsis
AU2003291403A1 (en) 2002-11-08 2004-06-03 Neurogen Corporation 3-substituted-6-aryl pyridined as ligands of c5a receptors
AU2003902354A0 (en) 2003-05-15 2003-05-29 Harkin, Denis W. Treatment of haemorrhagic shock
JP2006527756A (ja) 2003-06-19 2006-12-07 ファイザー・プロダクツ・インク Ｎｋ１拮抗薬
WO2005007087A2 (en) 2003-07-03 2005-01-27 Neurogen Corporation Substituted (heterocycloalkyl)methyl azole derivatives as c5a receptor modulators
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
EA200700117A1 (ru) 2004-06-24 2007-06-29 Инсайт Корпорейшн N-замещенные пиперидины и их применение в качестве фармацевтических препаратов
US7635698B2 (en) 2004-12-29 2009-12-22 Millennium Pharmaceuticals, Inc. Compounds useful as chemokine receptor antagonists
EP1853586B1 (en) 2005-02-18 2013-07-24 AstraZeneca AB Antibacterial piperidine derivatives
US7880004B2 (en) 2005-09-15 2011-02-01 Bristol-Myers Squibb Company Met kinase inhibitors
US20070112015A1 (en) 2005-10-28 2007-05-17 Chemocentryx, Inc. Substituted dihydropyridines and methods of use
ES2597843T3 (es) 2005-11-24 2017-01-23 Dompé Farmaceutici S.P.A. Derivados de (R)-arilalquilamino y composiciones farmacéuticas que los contienen
US20090220508A1 (en) * 2006-03-15 2009-09-03 Alexion Pharmaceuticals, Inc. Treatment Of Paroxysmal Nocturnal Hemoglobinuria Patients By An Inhibitor Of Complement
WO2008022060A2 (en) 2006-08-14 2008-02-21 Novartis Ag Imidazo-pyridine derivatives for modulating protein kinase activity
US20100190824A1 (en) 2007-06-29 2010-07-29 Prabhat Kumar Novel Substituted Piperidones as HSP Inducers
CA2737219C (en) 2008-08-11 2017-02-28 Tracy Keller Halofuginone analogs for inhibition of trna synthetases and uses thereof
US20110172126A1 (en) 2008-09-03 2011-07-14 Xenome Ltd Libraries of peptide conjugates and methods for making them
US20100074863A1 (en) 2008-09-17 2010-03-25 Yat Sun Or Anti-infective pyrrolidine derivatives and analogs
EP3508477B1 (en) 2008-12-22 2021-11-10 ChemoCentryx, Inc. C5ar antagonists
US20110275639A1 (en) 2008-12-22 2011-11-10 Chemocentryx, Inc. C5aR ANTAGONISTS
WO2011035143A2 (en) 2009-09-17 2011-03-24 The Regents Of The University Of Michigan Methods and compositions for inhibiting rho-mediated diseases and conditions
US8147400B1 (en) * 2011-01-17 2012-04-03 Coloplast A/S Penile implant with dilatant liquid
EA201590053A1 (ru) * 2012-06-20 2015-08-31 Новартис Аг Модуляторы пути системы комплемента и их применение
US20160060351A1 (en) 2013-05-08 2016-03-03 Novo Nordisk A/S Use of C5AR Antagonists
EP3200791B1 (en) 2014-09-29 2020-04-22 ChemoCentryx, Inc. Processes and intermediates in the preparation of c5ar antagonists
MA43872A (fr) 2016-01-14 2021-05-19 Chemocentryx Inc Procédé de traitement d'une glomérulopathie à c3
WO2017176620A2 (en) 2016-04-04 2017-10-12 Chemocentryx, Inc. SOLUBLE C5aR ANTAGONISTS
IL303776A (en) 2020-12-21 2023-08-01 Chemocentryx Inc Treatment of C3 glomerulopathy using a C5A inhibitor

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2197288C2 (ru) * 1999-08-03 2003-01-27 Тверская медицинская академия Способ лечения больных хроническим гломерулонефритом
US20100104558A1 (en) * 2006-10-31 2010-04-29 Inserm (Inetitut National De La Sante Et La Recherche Medicale ) Use of an EGFR Antagonist for the Treatment of Glomerolonephritis
US20120225056A1 (en) * 2008-11-10 2012-09-06 Alexion Pharmaceuticals, Inc. Methods and compositions for treating complement-associated disorders
US20130172347A1 (en) * 2010-06-24 2013-07-04 Pingchen Fan C5ar antagonists

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Hong Xiao et al. "C5a Receptor (CD88) Blockade Protects against MPO-ANCA GN", Journal of the American Society of Nephrology, 2013, Vol. 25, No. 2, P. 225-231. *
Le Quintrec et al. "Eculizumab for Treatment of Rapidly Progressive C3 Glomerulopathy", American Journal of Kidney Diseases, 2014, Vol. 65, No. 3, P. 484-489. *
Le Quintrec et al. "Eculizumab for Treatment of Rapidly Progressive C3 Glomerulopathy", American Journal of Kidney Diseases, 2014, Vol. 65, No. 3, P. 484-489. Hong Xiao et al. "C5a Receptor (CD88) Blockade Protects against MPO-ANCA GN", Journal of the American Society of Nephrology, 2013, Vol. 25, No. 2, P. 225-231. *

Also Published As

Publication number Publication date
SG11201805828YA (en) 2018-08-30
AU2017207359C1 (en) 2022-09-01
US20190201388A1 (en) 2019-07-04
ES3026359T3 (en) 2025-06-11
BR112018014222A2 (pt) 2018-12-11
JP2023126235A (ja) 2023-09-07
TW201726134A (zh) 2017-08-01
IL260539B (en) 2021-05-31
US11285138B2 (en) 2022-03-29
US20220354837A1 (en) 2022-11-10
AU2017207359A1 (en) 2018-07-26
JP7788814B2 (ja) 2025-12-19
CA3010735A1 (en) 2017-07-20
EP3402486A1 (en) 2018-11-21
CA3010735C (en) 2023-06-13
MX2018008624A (es) 2018-12-10
AU2017207359B2 (en) 2022-04-14
KR20180102642A (ko) 2018-09-17
JP2021183625A (ja) 2021-12-02
US11779576B2 (en) 2023-10-10
RU2018129378A (ru) 2020-02-14
JP2019501935A (ja) 2019-01-24
CN108601790A (zh) 2018-09-28
JP2024110998A (ja) 2024-08-16
ZA201804513B (en) 2024-01-31
EP3402486B1 (en) 2025-03-19
EP3402486C0 (en) 2025-03-19
JP7339733B2 (ja) 2023-09-06
US20170202821A1 (en) 2017-07-20
MX2022006069A (es) 2023-01-12
WO2017123716A1 (en) 2017-07-20
BR122024002810A2 (pt) 2024-03-12
TWI791423B (zh) 2023-02-11
RU2018129378A3 (enExample) 2020-05-20
EP3402486A4 (en) 2019-08-28
KR102767008B1 (ko) 2025-02-11
NZ744083A (en) 2022-07-01
MA43872A (fr) 2021-05-19

Similar Documents

Publication Publication Date Title
RU2742888C2 (ru) Способ лечения с3-гломерулопатии
RU2748260C2 (ru) РАСТВОРИМЫЕ С5аR АНТАГОНИСТЫ
KR20190113955A (ko) 장-외 증상을 갖는 염증성 장질환의 치료를 위한 화합물 및 방법
WO2018098353A1 (en) Method of treating focal segmental glomerulosclerosis
KR20200109297A (ko) 소변 sCD163의 C5aR 억제제 감소
US20220257580A1 (en) Treatment of c3 glomerulopathy using a c5a inhibitor
HK1262045A1 (en) Ccx168 for use in the treatment of c3 glomerulopathy
HK1262045B (en) Ccx168 for use in the treatment of c3 glomerulopathy
HK40089184A (zh) 使用c5a抑制剂治疗c3肾小球病
JPWO2000003703A1 (ja) 新規なアレルギー疾患治療剤